IN8bio GBM data shows mOS above 19.5 months in repeat-dose patients
IN8bio has reported a cluster of clinical and preclinical advances across its gamma-delta (γδ) T cell portfolio, headlined by updated survival data in newly diagnosed glioblastoma and the continued progression of its next-generation T cell engager platform toward in vivo testing.
The New York-listed company said patients with newly diagnosed glioblastoma (GBM) who received repeat dosing of its DeltEx Drug Resistant Immunotherapy (DRI) showed a median overall survival exceeding 19.5 months, still climbing at the time of reporting, compared with 13.2 months for contemporaneously enrolled patients on standard of care alone. Approximately 43% of repeat-dose patients remained alive at 24 months, versus 20% on standard of care. Median progression-free survival in the repeat-dose cohort was 13.0 months against 6.6 months for the control group.
These data were first presented at the 2026 American Society of Clinical Oncology Annual Meeting and subsequently published in peer-reviewed form in The Journal of Clinical Oncology, marking the first such publication for the DeltEx DRI programme in GBM. The company said no dose-limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity syndrome were observed in the Phase 1 study.
Translational evidence and TCE pipeline
Additional translational analyses, integrating artificial intelligence-assisted spatial proteomics, immunogenomics and transcriptomics, were presented at the ISCT and ASGCT annual meetings. IN8bio reported an 18-fold increase in intratumoral CD8+ T cell density and a 90% reduction in immunosuppressive granulocytes following repeated DeltEx DRI dosing, findings the company says provide mechanistic support for the clinical activity seen in the trial.
On the earlier-stage side, IN8bio is advancing INB-619, a CD19-targeting γδ T cell engager from its INB-600 platform, into IND-enabling studies. Preclinical data showed complete B cell depletion and robust γδ T cell expansion with minimal cytokine release, including low levels of IL-6 and TNF-alpha. The company said initial in vivo preclinical data for INB-619 are expected in the second half of 2026.
Chief executive William Ho said the quarter represented "an important period of scientific and clinical validation" for γδ T cell therapeutics, noting the company remains focused on seeking a regulatory pathway for its GBM programme.
Market context and regulatory watch
Glioblastoma remains one of oncology's most intractable indications, with a five-year survival rate below 10% and no meaningful improvement in standard-of-care outcomes for nearly two decades since temozolomide was approved. That context makes IN8bio's survival signals notable, though the Phase 1 dataset is small and a randomised controlled trial would be required before any regulatory submission. The company said it expects to report on FDA discussions regarding potential regulatory pathways for DeltEx DRI in the coming months.
The broader γδ T cell field is attracting increasing attention as a potential alternative to conventional alpha-beta T cell therapies, partly because γδ T cells do not carry the risk of graft-versus-host disease associated with allogeneic approaches. Several academic spinouts and a handful of better-capitalised competitors are pursuing γδ T cell programmes, but the field remains early-stage and no γδ T cell therapy has yet received regulatory approval anywhere.
IN8bio ended the second quarter with $18.0 million in cash, down from $27.1 million at year-end 2025, at a quarterly burn rate of roughly $4.8 million. At that rate, the current cash position provides approximately nine to ten months of runway, making near-term regulatory clarity or a financing event a key watch point for investors.